DAWN
NASDAQ
US
Day One Biopharmaceuticals, Inc. - Common Stock
$21,45
▲ +$0,03
(+0,14%)
Vol. 1.4M
3
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$956.9M
ROE
-32,1%
Margine
-113,5%
D/E
0,00
Beta
-1,30
52W
$6–$14
Consenso Wall Street
13 analisti · Apr 20260
Acquisto forte
0
Compra
10
Mantieni
1
Vendi
2
Vendita forte
0,0%
Rating Compra
Grafico dei Prezzi
Titoli simili
BCRX
BioCryst Pharmaceuticals Inc
$1.6B
GRAL
Grail Inc
$3.3B
RLAY
Relay Therapeutics Inc
$1.5B
MLYS
Mineralys Therapeutics Inc
$2.9B
SNDX
Syndax Pharmaceuticals Inc
$1.8B
ADMA
ADMA Biologics Inc
P/E 20,7
$4.3B
RARE
Ultragenyx Pharmaceutical Inc
$2.2B
TYRA
Tyra Biosciences Inc
$1.4B
CLDX
Celldex Therapeutics Inc
$1.8B
AGIO
Agios Pharmaceuticals Inc
$1.6B
Utili
Tasso di battuta: 75,0%| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Dic 2025 | $-0,15 | $-0,21 | $-0,06 |
| Set 2025 | $-0,30 | $-0,19 | +$0,11 |
| Giu 2025 | $-0,36 | $-0,29 | +$0,07 |
| Mar 2025 | $-0,45 | $-0,35 | +$0,10 |
Ricavi e utili trimestrali
| Trimestre | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Ricavi | — | $29.2M | $30.8M | $33.9M | $39.8M | $53.7M |
| Utile netto | — | -$65.7M | -$36.0M | -$30.3M | -$19.7M | -$21.3M |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -19.0% | -19.0% | -19.0% | -19.0% | -32.0% | -32.0% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -89.4% | -50.6% | -50.6% | -50.6% | -113.5% | -113.5% |
| Gross Margin | 88.9% | 94.0% | 94.0% | 94.0% | 89.4% | 89.4% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 9.65 | 9.65 | 9.65 | 9.65 | 8.68 | 8.68 |
Rapporti chiave
ROA (TTM)
-28,2%
P/S (TTM)
7,16
P/B
2,5
EPS (TTM)
$-1,48
CF/Share
$-2,29
52W High
$13,53
52W Low
$5,64
$5,64
Intervallo 52 settimane
$13,53
Salute finanziaria
Flusso di cassa libero
-$14.1M
Debito netto
-$194.3M
Liquidità
$197.1M
Debito totale
$2.8M
Aggiornato al Dic 31, 2025
Як DAWN виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка DAWN vs аналоги Biotechnology
P/E
—
▼
0%
sotto
peer
(18,8)
vs Peer
vs Settore
Sottovalutato
P/S
7,2
▼
44%
sotto
peer
(12,9)
vs Peer
vs Settore
Sottovalutato
P/B
2,5
▲
3%
sopra
peer
(2,5)
vs Peer
vs Settore
Valore equo
Дивідендна дохідність
—
▼
0%
sotto
peer
(0,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість DAWN vs аналоги Biotechnology
ROE
-32,1%
▲
52%
sopra
peer
(-67,3%)
vs Peer
vs Settore
Sotto media
Net margin
-113,5%
▲
60%
sopra
peer
(-286,8%)
vs Peer
vs Settore
Sotto media
Валова маржа
89,4%
▲
14%
sopra
peer
(78,6%)
vs Peer
vs Settore
Debole
ROA
-28,2%
▲
40%
sopra
peer
(-46,7%)
vs Peer
vs Settore
Sotto media
Фінансове здоровʼя DAWN vs аналоги Biotechnology
D/E ratio
0,0
▼
0%
sotto
peer
(0,0)
vs Peer
vs Settore
Debito basso
Поточна ліквідність
8,7
▲
95%
sopra
peer
(4,4)
vs Peer
vs Settore
Liquidità forte
Beta
-1,3
▼
234%
sotto
peer
(1,0)
vs Peer
vs Settore
Più volatile
Радар фундаменталів DAWN
DAWN
Mediana peer
Industria
DAWN прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
DAWN vs аналоги: ключові метрики
Ultime notizie
Nessuna notizia correlata ancora